News Articles for Paul Anderson

This week's appointments include Meg O'Neill, Daniel Kiely, John Van Der Wielen, Paula Rogers, David Lock, Fiona Seaward, Jean Shaw, Craig Bydder, Peter Cutler, and Paul Anderson.

UPDATED: Outgoing Committee for Perth chief executive Paula Rogers has been appointed as the inaugural chair of a 12-member state government leadership group.

Perth biomedical firm Orthocell has gained a toehold in China for its nerve repair product via a deal with a Hong Kong-based medical products distributor.

Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.

Murdoch-based Orthocell has announced plans to raise $30 million, as it aims to build further momentum behind its US ambitions.

PPS Water Group founder Matthew Rear has been named Australia's top services entrepreneur at the 2026 EY Entrepreneur Of The Year awards.

WA biotech Orthocell has announced a promising new use case for its Remplir nerve regeneration product, this time in reducing post-surgical complications in prostate cancer sufferers.

A day after announcing a record quarterly revenue of $2.7 million, Perth medtech Orthocell has appointed a former Pilbara Minerals figure and ex-Olympian to its executive team.

Orthocell boss Paul Anderson has heralded the first surgical use of its Remplir nerve repair device in the US as a “significant milestone”.

The Perth biotech company has welcomed a US academic for a series of talks at universities across the country.

Murdoch-based Orthocell's push to expand the reach of its nerve repair product Remplir has continued, following news it has received regulatory approval in Hong Kong.

Orthocell boss Paul Anderson said the Murdoch-based biotech medical company is “well ahead” of its original targets in relation to US sales of its nerve repair product, Remplir.

Shares in Murdoch-based Orthocell rose by 15 per cent early on Wednesday, following news the biotech medical company had received regulatory approval to sell its nerve repair product in Canada.

Fresh from receiving clearance from the Food and Drug Administration to distribute its nerve repair product Remplir in the US earlier this month, Murdoch-based Orthocell has appointed an initial four distributors.

Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.

John Van Der Wielen-chaired Orthocell has received another timely boost, as it aims to further a push into Latin America.

Orthocell has received clearance from the US-based Food and Drug Administration to begin selling its nerve repair product Remplir in the country.

Singapore's Health Science Authority has granted regulatory approval for John Van Der Wielen-chaired Orthocell for use of its dental membrane project, Striate+.

Kim Beazley-backed medtech company Orthocell has flagged an expedited expansion into several jurisdictions after strong early sales of its Remplir nerve repair technology.

Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.

Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.

Biotech firm Orthocell is a step closer to its nerve repair device Remplir being approved in the US, following the completion of its US regulatory study.

Orthocell has struck a deal with a medical equipment supply firm to distribute its nerve repair device in Singapore, sending the Perth company's shares up 26 per cent.

Perth-based biotechnology firm Orthocell has raised $17 million to take its Remplir nerve regeneration product to the world's biggest healthcare market.

Murdoch-based Orthocell has received regulatory approval to commence sales of Remplir in Singapore, as the listed biotech company posts a second consecutive quarter of record revenue.

Perth-founded biotech company Orthocell has received regulatory approval to commence sales of its guided bone regeneration product Striate+ in Canada.

Orthocell has reported a record revenue of $1.84 million in the recent quarter, with the biotech company's annual growth up by more than 30 per cent.

Perth-based Orthocell has struck a 25-year licensing and distribution agreement valued at $23.1 million with a major dental implant company.

Perth-based biotherapeutic company Orthocell has received US approval for the use of its dental bone and tissue regeneration platform.

SPECIAL REPORT: As markets struggle under the pressure of the COVID-19 pandemic, the medtech industry has found itself with an unparalleled, if challenging, opportunity.

Bio-therapeutic company Orthocell has received commitments to raise $13 million from a share placement and up to a further $5 million from a share purchase plan, primarily to accelerate the commercialisation of its CelGro flagship product.

Orthocell has capitalised on a sustained rally in its share price to raise $10.6 million via a share placement at 40 cents per share.

Shares in Perth biotech Orthocell more than quadrupled in value today after the company released positive results from a trial of its nerve regeneration product.

Perth-based Orthocell has raised $4 million to fund ongoing development of its regenerative medicine products.

Shares in Perth-based Orthocell have soared after the tissue regeneration company was granted a patent for its "cell factory" technology in the United States.

Shares in Perth-based biotechnology company Orthocell have risen slightly on the back of it striking a partnership with leading Swedish medical technology company Bonesupport.

The recent publication of two listings of influential business leaders provided food for thought about the growing international influence on Western Australia.